ライフサイエンスコーパス: enrolment

1 ross 10 weeks all patients were screened for enrolment.

2 calTrials.gov, NCT02715531, and is closed to enrolment.

3 6 (84.5%) started therapy within 48 hours of enrolment.

4 ratory cultures in the previous 12 months at enrolment.

5 Conventional therapy was stopped upon enrolment.

6 24 (37.1%) deaths occurring within 7 days of enrolment.

7 ies per mL) and retention at 12 months after enrolment.

8 egative breast cancer was a prerequisite for enrolment.

9 s.gov, number NCT02560025, and has completed enrolment.

10 servations over the first 2 months following enrolment.

11 w York/15/5364 (NY15) based on their year of enrolment.

12 ided to women not using a reliable method at enrolment.

13 s or older with children aged 6-24 months at enrolment.

14 years), 357 (24%) had bacterial vaginosis at enrolment.

15 rst 90 days and deaths up to 12 months after enrolment.

16 one child had an HIV test within 4 weeks of enrolment.

17 treated with the same treatment allocated at enrolment.

18 including workforce participation and school enrolment.

19 ept 29, 2014, 795 patients were screened for enrolment.

20 (or similar) EEG no more than 7 days before enrolment.

21 any grass pollen AIT at least 5 years before enrolment.

22 to 2 years, and here we present findings at enrolment.

23 cribed insulin for at least 12 months before enrolment.

24 ents who are often profoundly debilitated at enrolment.

25 two vs three or more) during the year before enrolment.

26 s who were anaemic or malnourished at SUMMIT enrolment.

27 cancer by the study physician at the time of enrolment.

28 content were needed from all patients before enrolment.

29 aining regimens for at least 96 weeks before enrolment.

30 to repair a hip fracture, were eligible for enrolment.

31 imary outcome was mortality at 6 months from enrolment.

32 %) had received isoniazid prophylaxis before enrolment.

33 , NCT02954536, and is ongoing, but closed to enrolment.

34 ntify those suitable for NASH clinical trial enrolment.

35 RS-CoV-2 result were considered eligible for enrolment.

36 le (EDSS) score of 3.0-6.5 were eligible for enrolment.

37 one or more of days 0,3,7,14,21 +/-30 after enrolment.

38 udy and were aged 5 to less than 18 years at enrolment.

39 ov, NCT02595892, and is active but closed to enrolment.

40 Mortality risk was calculated 56 days from enrolment.

41 ssion, and no relapses in the 2 years before enrolment.

42 settings as well as settings with low school enrolment.

43 d per applicable standards were eligible for enrolment.

44 assessed for eligibility and 52 consented to enrolment.

45 were examined for atopic dermatitis (AD) at enrolment.

46 less than 50 copies per mL within 60 days of enrolment.

47 urable active disease within 1 year of study enrolment.

48 O-placebo group (mean change from global OLE enrolment -1.4, 95% CI -6.2 to 3.5).

49 f participants with moderate/high anxiety at enrolment (103/200, 52%), with mean 33.0 (SD 9.3) interv

50 s and sanitation practices, were recorded at enrolment (12th week of gestation).

51 the 164 women not using a reliable method at enrolment, 131 (80%) started using them during follow-up

52 uals subsequently found to be ineligible for enrolment, 142 patients in the individual hypnotherapy g

53 s of eight, stratified by gestational age at enrolment (17-25 weeks vs 26-34 weeks).

54 At enrolment, 176 (61%) of 287 HIV-positive women and 60 (4

55 2 weeks after enrolment, 26 (3%) of 1021 patients in the CPAP group, a

56 erformed at baseline, days 7, 14 and 21 post-enrolment (+/- 3 days where possible).

57 nib as the last BCR inhibitor therapy before enrolment, 43 of whom were enrolled in the main cohort a

58 -daily for 5 days, and we stratified them by enrolment 48 h versus 48-120 h since illness onset.

59 After enrolment, 823 women were randomly assigned to receive F

60 esign stratified by amount of haemoglobin at enrolment (above and below the median amount of haemoglo

61 ertiles with time to relapse following study enrolment, adjusting for several confounders.

62 of recurrent appendix mass within 1 year of enrolment after successful non-operative treatment of ap

63 tervention or to be waitlisted for programme enrolment after the study period and serve as the contro

64 identical to lamotrigine dose prior to study enrolment); after each 14-day period, patients were cros

65 Before enrolment, all patients had received 3-18 months of imat

66 ogical malignancies have the lowest rates of enrolment among patients with any tumour subtype.

67 re scheduled clinic visits by 18 months post-enrolment (among all participants).

68 s after intervention delivery (2 years after enrolment) among children younger than 5 years.

69 ipant withdrew from the trial 240 days after enrolment and 12 died during follow-up (five in the inte

70 association between hyperglycaemia and TB at enrolment and 3 months after TB treatment in the context

71 oup were excluded due to ineligibility after enrolment and 61 were evaluable.

72 M prevalence was 11.9% (95% CI: 9.1-15.4) at enrolment and 9.3% (95% CI: 6.4-13) at follow-up; IGR pr

73 e either point-of-care viral load testing at enrolment and after 6 months with task shifting to enrol

74 ar inflammation was clinically quantified at enrolment and all follow-up visits.

75 re measured for all groups in the mothers at enrolment and at 1 month after each vaccine dose, and in

76 cental growth factor (PlGF) were measured at enrolment and delivery in a trial comparing SPAZ to SP p

77 In a nested study, paired enrolment and delivery plasma samples from 681 women wer

78 ies to recombinant antigens declined between enrolment and delivery, antibodies directed against IEs

79 Between enrolment and delivery, antibodies to recombinant antige

80 Risk factor data were collected at enrolment and during follow-up.

81 iagnosed less than 1 year before the date of enrolment and excluded patients with any other malignanc

82 I 42.2-51.8) and 21.5% (95% CI 16.9-26.3) at enrolment and follow-up.

83 proxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL

84 proxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL

85 who had a stroke within the 3 months before enrolment and had mild-to-moderate upper extremity motor

86 non-linkers, six had not initiated ART upon enrolment and no acquired DRMs were detected.

87 to the presence of dysphagia at the time of enrolment and not by site of onset of symptoms.

88 ared risk of death during the period between enrolment and one follow-up household visit done about 6

89 terviews were conducted with participants at enrolment and over 3 months to determine how self-tests

90 though the trial is ongoing in other strata, enrolment and planned follow-up is complete for strata 1

91 s attended study visits at ages 6 weeks (for enrolment and randomisation), 10 weeks, 14 weeks, and th

92 165 mm Hg and diastolic 85-105 mm Hg at both enrolment and randomisation, and a mean 24 h blood press

93 because their parents withdrew consent after enrolment and randomisation, so 939 infants actually rec

94 glutamic acid and carnitine at 24 hrs after enrolment and significantly lower plasma glutamic acid c

95 The study has completed enrolment and the final analysis of overall survival is

96 f 16 369 matched controls died between study enrolment and the follow-up visit at about 60 days (haza

97 tcome was treatment failure within 7 days of enrolment and the primary analysis was per protocol.

98 ad to be clinically free of breast cancer at enrolment and without evidence of recurrent disease at a

99 uals subsequently found to be ineligible for enrolment), and assessed non-inferiority of group hypnot

100 y (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day bre

101 s trial was done between Dec 15, 2015 (first enrolment), and May 19, 2016 (final visit of the last en

102 ong those who started ART within 6 months of enrolment); and the proportion who missed two or more sc

103 ) underwent transplantation within 1 year of enrolment, and 5 of 51 patients died.

104 m smear grade 1+ or higher were eligible for enrolment, and a molecular assay (GeneXpert or MTBDRplus

105 2 diabetes diagnosed within 2 years prior to enrolment, and centrally confirmed glycated haemoglobin

106 The global OLE is ongoing with no new enrolment, and current findings are based on the interim

107 The open-label phase is ongoing with no new enrolment, and current findings are based on the prespec

108 sults, and HIV test results were recorded at enrolment, and each participant gave at least three sput

109 5-40 years of age, 17-34 weeks' gestation at enrolment, and had not previously received any influenza

110 ani grade 2 or 3, disease progression before enrolment, and no previous chemotherapy for sarcoma or p

111 therapy adherence, no substance use, school enrolment, and no sexual abuse) were not associated with

112 identifying participants, obtaining consent, enrolment, and outcome assessments were masked to alloca

113 articipants were aged 2-14 years, healthy at enrolment, and recruited before the initiation of the pr

114 aecal samples to identify enteropathogens at enrolment, and we performed a follow-up home visit about

115 od cells for the past 2 years at the time of enrolment, and were receiving deferoxamine (<100 mg/kg p

116 ontrolled period was stopped before complete enrolment, as recommended by the independent data-monito

117 gned to the 60 mg group were excluded due to enrolment before version 6.0 of the protocol; the remain

118 ancer QLQ-C30 and QLQ-OV28 questionnaires at enrolment, before each chemotherapy cycle, then 6-weekly

119 Study enrolment began in January, 1994, and two cohort studies

120 Enrolment began on April 4, 2007, and was halted on Apri

121 Trial enrolment began on March 30, 2012, and was completed on

122 ilippines, Japan, and Korea; 46 centres with enrolment between 1 October 2012 and 6 October 2016), we

123 This study is closed to enrolment but patients' treatment and follow-up is ongoi

124 The study is closed for enrolment but treatment and follow-up of patients is ong

125 The study has completed enrolment, but patients are still in follow-up for overa

126 On days when trial enrolment capacity was reached, patients were enrolled i

127 anial haemorrhage less than 12 months before enrolment, clinically significant cardiovascular disease

128 ing group had HIV testing on the same day as enrolment, compared with 248 (13%) of 1951 in the standa

129 In this ongoing (enrolment complete) randomised, placebo-controlled, phas

130 analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017).

131 ow the median amount of haemoglobin on every enrolment day) and stage of gestation (14-18 weeks vs 19

132 eral artery tonometry are being performed at enrolment, defervescence, and follow-up FINDINGS: To dat

133 outcome was treatment failure by day 8 after enrolment, defined as clinical deterioration, developmen

134 response system, and stratified by region of enrolment (east Asia vs rest of world), ECOG performance

135 a web-based data entry system that confirmed enrolment eligibility to inhaled 7% hypertonic saline or

136 ulation for the efficacy analyses because of enrolment error.

137 s of Barrett's oesophagus at 12 months after enrolment, expressed as a rate per 1000 person-years, in

138 ort (one patient), or too late for the trial enrolment (five patients).

139 aviours using questionnaires administered at enrolment, follow up, and graduation visits.

140 The trial is active, but closed to enrolment; follow-up for patients who completed treatmen

141 Enrolment for patients with gastric or gastro-oesophagea

142 Enrolment for patients with HER2-positive breast cancer

143 Enrolment for PROSPER is complete and follow-up continue

144 Enrolment for RADIANT-4 was completed on Aug 23, 2013, b

145 Enrolment for the full trial is ongoing.

146 Here, we report results from phase 2; enrolment for the study began on Feb 16, 2010, and ended

147 Enrolment for this trial is closed and results of the fi

148 dyads (87% of the 1489 dyads in the original enrolment) for assessment when the child was 4 years of

149 e screened 1570 mother-child pairs for study enrolment, from whom (78%) eligible infants were enrolle

150 the time of database lock (April 11, 2018), enrolment had closed and the study was ongoing, with 21

151 9, 2003, were aged 18 years old and older at enrolment, had a minimum follow-up of 10 years after dia

152 MGTX patients were aged 18 to 65 years at enrolment, had generalised non-thymomatous myasthenia gr

153 Enrolment has been completed, and follow-up is ongoing.

154 At antenatal enrolment higher CRP (adjusted odds ratio 1.52; 95% conf

155 sic Hodgkin lymphoma were eligible for study enrolment if they were 60 years or older, or younger tha

156 Women were eligible for enrolment if they were aged 16 years and older, diagnose

157 Patients were eligible for enrolment if they were aged 18 years or older, had a con

158 Hospice enrolment improves quality of life for patients with adv

159 The TB/DM association was significant at enrolment in both new and pre-existing DM, but only pers

160 ex, CD4 cell count, and WHO disease stage at enrolment in care and initiation of antiretroviral thera

161 here we describe our results after extending enrolment in children to compare outcomes in three age g

162 options for patients with brain metastases, enrolment in clinical trials is essential to advance our

163 nosis, those without 12 months of continuous enrolment in medical and pharmacy benefits, and those wh

164 significant TB/DM and TB/IGR association at enrolment in newly diagnosed DM, but persistent hypergly

165 as all-cause mortality rate at 2 weeks after enrolment in patients for whom data were available after

166 fore ICD implantation or on the day of study enrolment in patients who were conservatively managed.

167 in programme eligibility rules that limited enrolment in SMSXXI to children born after Dec 1, 2006.

168 Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from

169 previous injecting drug users at the time of enrolment in the BTS, were offered daily oral tenofovir

170 5928 (76%) women were eligible for enrolment in the extension, and of these, 4550 (77%) wer

171 data from 12 963 children aged 9-14 years at enrolment in the Growing Up Today Study, and their mothe

172 ansplant waiting time for patients following enrolment in the HCV protocol was 20 days (IQR 8-57).

173 tal between 2005 and 2014 and had continuous enrolment in the KPNC system for at least four years (n

174 h at least 12 months of continuous insurance enrolment in the previous year, 12-month follow-up, and

175 Three years after enrolment in the RCT, mortality dates of all surgical pa

176 nal analysis is based on assessments done at enrolment in the subset of non-manifesting carriers of L

177 tion of corticosteroids was not required for enrolment in this study.

178 independent core laboratory at completion of enrolment, in all randomly allocated participants who ha

179 Enrolment into ARIEL2 Part 1 is complete, although an ex

180 stroke and patients who may be targeted for enrolment into clinical trials comparing anticoagulation

181 Registry Integrating Datasets, Genomics, and Enrolment into Clinical Trials) registry in Dundee, UK.

182 io that assumed POC testing did not increase enrolment into community ART delivery produced ICERs tha

183 ed viral suppression by 9 percentage points, enrolment into community-based ART delivery by 25 percen

184 nsitive to changes in intervention impact on enrolment into community-based ART delivery.

185 o restrictions on current renal function for enrolment into iPrEx OLE, in which participants were giv

186 after 12 weeks in order to be considered for enrolment into the extension study.

187 Enrolment into the higher dose groups occurred after a s

188 Patient enrolment into the phase 1 trial was from June 20, 2005,

189 as from June 20, 2005, to Sept 15, 2009, and enrolment into the phase 2 trial was from Feb 9, 2010, t

190 stage of this Simon two-stage design trial; enrolment into the second stage is continuing.

191 network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Proj

192 or screening children on suppressive ART for enrolment into therapeutic vaccine trials and other prot

193 Enrolment into this cohort is closed, but patients are s

194 tatic urothelial carcinoma were screened for enrolment into this study; 249 patients were eligible an

195 Study enrolment is closed and overall survival follow-up is in

196 ith ClinicalTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment

197 Enrolment is complete and this report represents the fin

198 Patient enrolment is complete, although treatment and collection

199 Enrolment is complete, and the study is ongoing.

200 Patient enrolment is complete, and the study is registered with

201 Patient enrolment is complete, but follow-up is ongoing.

202 Clinical Trial Registry, ISRCTN43811467, and enrolment is complete.

203 ed with ClinicalTrials.gov, NCT02924376, and enrolment is completed.

204 ipants have been enrolled in the project and enrolment is on-going.

205 0, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing).

206 than 1, major surgery within 4 weeks before enrolment, known CNS involvement of lymphoma, and uncont

207 In CLTS villages, younger children at enrolment (<2 years) showed greater improvements in heig

208 e of malaria in this group was also lower at enrolment, making interpretation of the effect of IST ch

209 At enrolment, malaria prevalence was lower in IST (5.7%) th

210 protein-energy (PE), or PE + MMN daily from enrolment (mean [SD] 13.7 [3.3] weeks' gestation) until

211 of outpatients tested for HIV on the day of enrolment, measured through exit surveys with a sample o

212 ted on Feb 16, 2014, before reaching planned enrolment (n=150) because of poor efficacy.

213 Enrolment, neoadjuvant therapy, and surgery have been co

214 tion, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% o

215 The trial was stopped after the enrolment of 1884 patients of an anticipated 4000 patien

216 After enrolment of 302 episodes (68.6% of the planned sample s

217 The trial was terminated early after enrolment of 3232 patients due to severe allergic reacti

218 reening is paramount for early diagnosis and enrolment of affected children into a comprehensive care

219 6 weeks after enrolment of index patients, 392 (67%) of 586 partners h

220 Enrolment of women continued for the duration of the blo

221 or their recent history (within 24 weeks of enrolment) of bacterial sexually transmitted infections.

222 We began enrolment on April 24, 2013, and completed follow-up on

223 From start of enrolment on April 24, 2014, to close of trial on May 10

224 In DR Congo, we started enrolment on Sept 17, 2012, and continued until June 28,

225 reas, in SST clusters, they were screened at enrolment only.

226 ilst TB/IGR association was only positive at enrolment OR 2.3 (95% CI 1.6-3.3).

227 Couples who were pregnant at enrolment or had been previously diagnosed as infertile

228 ed history of coughing in the source case at enrolment (OR 1.6; 95% CI: 1.1-2.3).

229 TB/DM association was significant at enrolment (OR 2.41 (95% CI 1.3-4.3)) and follow-up (OR 3

230 nd satisfactory decision about their child's enrolment, or non-participation, in cancer clinical tria

231 urs worked), cognition, literacy, and school enrolment owing to very low certainty evidence.

232 Before enrolment, participants had achieved a weight loss of >=

233 At study enrolment, patients from GALATHEA and TERRANOVA were age

234 After enrolment, patients received 6 weeks of medication optim

235 een 30 March 2015 and 30 June 2017, with the enrolment period ending on 31 July 2016.

236 The original enrolment period included children born in the study are

237 and assessed them for cognitive function at enrolment (pre-treatment), and again after 8 weeks of tr

238 eceived 500 mg calcium or placebo daily from enrolment prepregnancy until 20 weeks' gestation.

239 On univariate analysis increasing age at enrolment, previous squamous cell carcinoma, having the

240 ree survival at 12 months and 24 months from enrolment, progression-free survival, and overall surviv

241 d Patient Data Collection, and public school enrolment records, as part of the Seeding Success study.

242 ipants who reported being sexually active at enrolment reported abstinence at their follow-up visit (

243 ticipants who reported not using a condom at enrolment reported using condoms at their first follow-u

244 no substance use, HIV care retention, school enrolment, school progression, no sexual abuse, no high-

245 Increased enrolment sFlt1:PlGF ratios associated with LBW in all w

246 tcome and supported early closing of patient enrolment, since this analysis indicated that the full p

247 caused the data monitoring committee to stop enrolment six patients short of target.

248 children younger than 5 years, regardless of enrolment status.

249 Ocular complications were more frequent at enrolment than at discharge (142 [18%] vs 61 [8%] patien

250 At enrolment, the median age was 15 years (IQR 14-17), 52%

251 ticipants who started ART within 6 months of enrolment, the proportion who died or had a viral load o

252 Following enrolment, the recipient's status on the heart transplan

253 The study is closed to enrolment; this report focuses on the cohort with small-

254 nts were masked to treatment assignment from enrolment through week 41 (time of the last injection).

255 rhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-

256 Patients were followed from study enrolment to 1 year after transplantation.

257 allocation made home visits every week from enrolment to 6 months after delivery.

258 wer-achieving students and increased overall enrolment to advanced mathematics courses in a nationall

259 Median time from enrolment to ART initiation was 0 days (IQR 0-8).

260 n outcomes were ART uptake, time from cohort enrolment to ART initiation, and retention in care and v

261 Participants were interviewed 6 months after enrolment to ascertain whether they sought HIV care, ver

262 ed to attend a follow-up visit 1 month after enrolment to assess social harms and sexual behaviour.

263 Enrolment to expanded cohorts of those subtypes is ongoi

264 (1:1) by a computer-generated assignment at enrolment to receive a programme of structured, task-ori

265 Infants were randomly assigned (1:1) at enrolment to receive oral 10 mg/kg azithromycin or place

266 owed up patients at 6 months and 1 year from enrolment to record symptoms, medications, and outcomes.

267 Trained clinicians assessed patients at enrolment to the cohort, recording clinical symptoms and

268 p until death or July 31, 2018 (date of last enrolment to the DCSS).

269 The outcome of the study was time from enrolment to the next relapse.

270 pairwise randomisation according to order of enrolment) to receive either stimulation on-first or sti

271 On the basis of enrolment trends, ongoing review of study data, and evol

272 nded that treatment should be continued from enrolment until the infant's birth.

273 and different exposures were collected upon enrolment using validated questionnaires.

274 vital capacity >10% at 12 months after study enrolment) using a repeated measures model.

275 Since the timing of KYT enrolment varied for each patient, the primary outcome m

276 they were breastfeeding at the screening and enrolment visits, and their mother was planning to breas

277 Dietary intake during the week before enrolment was assessed with the validated Block Kids Foo

278 Treatment failure within 7 days of enrolment was reported in 90 (12%) infants who received

279 2015, 86 patients were randomly assigned but enrolment was stopped because of funding reasons.

280 were more common than anticipated, and trial enrolment was stopped early.

281 panib crossed the predetermined boundary and enrolment was stopped.

282 bility of survival to day 14 of </=0.55, and enrolment was stopped.

283 Enrolment was voluntarily halted on Feb 16, 2014, before

284 erate-transmission settings with good school enrolment, we find that school-based treatment is suffic

285 ry of exacerbations in the year before study enrolment, we identified several novel biomarkers associ

286 After completion of enrolment, we implemented an mOPV2 vaccination campaign

287 Key inclusion criteria for enrolment were Eastern Cooperative Oncology Group perfor

288 those with organic disease identified after enrolment were excluded from the modified intention-to-t

289 lable prospective relapse data subsequent to enrolment were included in this project.

290 prison during the 3 months before open-label enrolment were more likely to return for at least one op

291 Inclusion criteria for enrolment were: age 18 years or older, weight at least 5

292 , and Gender Parity Index for primary school enrolment) were also examined.

293 had fallen at least once in the year before enrolment, were able to walk 18 m without an aid, had no

294 low up was 197 days (IQR 187-209 days) after enrolment, which corresponded to 255 days (228-287) afte

295 e-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive

296 had at least 2 years of previous health plan enrolment with at least one outpatient visit from Jan 1,

297 ts (median 2 cycles commencing 359 days from enrolment) with PSA decline >= 50% in 11 patients (73%).

298 en aged 2-5 years, weighing at least 8 kg at enrolment, with a confirmed diagnosis of cystic fibrosis

299 nts were assigned to each cohort in order of enrolment, with the first three patients being assigned

300 elected into one of seven open groups during enrolment without randomisation.